

## Accepted Manuscript

Title: Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS

Authors: Marie-Noëlle Paludetto, Florent Puisset, Félicien Le Louedec, Ben Allal, Thierry Lafont, Etienne Chatelut, Cécile Arellano



PII: S0731-7085(17)32892-3  
DOI: <https://doi.org/10.1016/j.jpba.2018.03.013>  
Reference: PBA 11844

To appear in: *Journal of Pharmaceutical and Biomedical Analysis*

Received date: 22-11-2017  
Revised date: 16-2-2018  
Accepted date: 6-3-2018

Please cite this article as: Marie-Noëlle Paludetto, Florent Puisset, Félicien Le Louedec, Ben Allal, Thierry Lafont, Etienne Chatelut, Cécile Arellano, Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS, *Journal of Pharmaceutical and Biomedical Analysis* <https://doi.org/10.1016/j.jpba.2018.03.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS

Marie-Noëlle Paludetto<sup>1,2,3</sup>, Florent Puisset<sup>1,2,3</sup>, Félicien Le Louedec<sup>1</sup>, Ben Allal<sup>1,2</sup>, Thierry Lafont<sup>1,2</sup>, Etienne Chatelut<sup>1,2</sup>, Cécile Arellano<sup>1\*</sup>

<sup>1</sup> Team 14, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France

<sup>2</sup> Institut Claudius Regaud, IUCT-O, Toulouse, France

<sup>3</sup> Pharmacy department, IUCT-O, Toulouse, France

\* Corresponding author

## Highlights

- Microsomal incubations to obtain non-commercial metabolites
- Simultaneous determination of pazopanib and its metabolites
- Semi-quantification of pazopanib metabolites

## Abstract:

Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) approved as first line treatment for patients with advanced renal cell carcinoma (RCC) and as second-line treatment of patients with advanced soft

Download English Version:

<https://daneshyari.com/en/article/7626958>

Download Persian Version:

<https://daneshyari.com/article/7626958>

[Daneshyari.com](https://daneshyari.com)